CAMBRIDGE, Mass. and
BOULDER, Colo., July 27, 2021
/PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT),
a biotechnology company focused on developing precision therapies
for genetically defined diseases, today announced that Andrew Robbins, Chief Executive Officer and
President, will present at the Wedbush PacGrow Healthcare
Conference on Tuesday, August
10th, from 10:55 -11:25am
ET.
Access to the webcast of this event, as well as an archived
recording, will be available under the "Events" tab on the investor
relations section of the Cogent Biosciences website at:
https://investors.cogentbio.com/events.
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing
precision therapies for genetically defined diseases. The most
advanced clinical program, bezuclastinib, is a selective tyrosine
kinase inhibitor that is designed to potently inhibit the KIT D816V
mutation as well as other mutations in KIT exon 17. KIT D816V is
responsible for driving systemic mastocytosis, a serious disease
caused by unchecked proliferation of mast cells. Exon 17 mutations
are also found in patients with advanced gastrointestinal stromal
tumors (GIST), a type of cancer with strong dependence on oncogenic
KIT signaling. In addition to bezuclastinib, the newly formed
Cogent Research team is developing a portfolio of novel targeted
therapies to help patients fighting serious, genetically driven
diseases. Cogent Biosciences is based in Cambridge, MA and Boulder, Co. Visit our website for more
information at www.cogentbio.com. Follow Cogent Biosciences on
social media: Twitter and LinkedIn. Information that may be
important to investors will be routinely posted on our website and
Twitter.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cogent-biosciences-to-present-at-wedbush-pacgrow-virtual-healthcare-conference-2021-301341731.html
SOURCE Cogent Biosciences, Inc.